908 Devices
Tony J. Hunt is President and CEO, and a member of the board of directors, of Repligen Corporation (Nasdaq: RGEN), a bioprocessing-focused life sciences company. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations, and was named to his current position in May 2015. Prior to Repligen, Tony was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Tony was with Applied Biosystems as Senior Director of Pharma Programs where he launched the pharma analytics business that in 2008 became a part of the bioproduction platform at Life Technologies.
Tony holds a B.S. in microbiology and an M.S. in biotechnology from University College in Galway, Ireland, and an MBA from Boston University School of Management.
This person is not in the org chart
This person is not in any offices
908 Devices
908 Devices, is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets.